Supernus Pharmaceuticals (NASDAQ:SUPN) Announces Earnings Results, Misses Expectations By $0.32 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.32), FiscalAI reports. Supernus Pharmaceuticals had a negative net margin of 5.36% and a positive return on equity of 12.26%. The firm had revenue of $190.80 million for the quarter, compared to analysts’ expectations of $192.92 million.

Supernus Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ SUPN traded up $0.40 during midday trading on Tuesday, reaching $49.03. The company had a trading volume of 1,105,499 shares, compared to its average volume of 695,461. The business’s 50-day simple moving average is $51.14 and its 200 day simple moving average is $49.90. The stock has a market cap of $2.82 billion, a P/E ratio of -72.10, a P/E/G ratio of 0.94 and a beta of 0.57. Supernus Pharmaceuticals has a 1 year low of $29.16 and a 1 year high of $59.68.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 4,475 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total value of $228,269.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Georges Gemayel sold 10,000 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00. Following the completion of the transaction, the director directly owned 28,159 shares of the company’s stock, valued at approximately $1,512,419.89. This represents a 26.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 120,881 shares of company stock valued at $6,139,356. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter worth $51,000. Raymond James Financial Inc. purchased a new position in shares of Supernus Pharmaceuticals during the second quarter worth $55,000. Osaic Holdings Inc. raised its holdings in shares of Supernus Pharmaceuticals by 211.5% during the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after purchasing an additional 1,328 shares during the last quarter. Vestcor Inc purchased a new position in shares of Supernus Pharmaceuticals during the third quarter worth $67,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Supernus Pharmaceuticals during the third quarter worth $128,000.

Analyst Ratings Changes

SUPN has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.